Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 4/20 | 0.49 |
| ▸ | NPY2R | P49146 | 3/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463258 | 0.88 | SIRT5 (0.52) | TFPIIL23RNPY2RKISS1R | |
| SCHEMBL15185999 | 0.87 | TFPI (0.52) | TFPIIL23RRXFP1 | |
| SCHEMBL30855554 | 0.86 | NPY4R (0.45) | TFPIIL23RNPY2RKISS1R | |
| SCHEMBL31238569 | 0.86 | IL23R (0.51) | TFPIIL23R | |
| SCHEMBL30140921 | 0.86 | TFPI (0.48) | TFPIKEAP1 | |
| SCHEMBL16508141 | 0.85 | TFPI (0.49) | TFPIIL23RKEAP1NPY2RKISS1R | |
| SCHEMBL16508109 | 0.85 | TFPI (0.49) | TFPIIL23RKEAP1NPY2RKISS1R | |
| SCHEMBL30531635 | 0.85 | NPY4R (0.56) | KEAP1NPY2R | |
| SCHEMBL30531632 | 0.85 | NPY4R (0.56) | KEAP1NPY2R | |
| SCHEMBL30531636 | 0.85 | SIRT5 (0.51) | TFPIIL23RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | TFPI 2646/4885IL23R 1779/4885KEAP1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.